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Objective To define the synovial characteristics of
patients with rheumatoid arthritis (RA) and psoriatic
arthritis (PsA) in clinical and ultrasound remission
achieved by combination therapy with methotrexate
(MTX) and tumour necrosis factor (TNF) blockers.
Methods Patients with RA in remission (n=25)
(disease activity score (DAS)<1.6 for at least 6 months),
patients with RA in low disease activity (LDA) (n=10)
(1.6<DAS<2.4 for at least 6 months) and patients with
PsA in remission (n=18) (DAS<1.6 and Psoriasis Area
Severity Index (PASI)=0 for at least 6 months) achieved
by MTX+anti-TNF (adalimumab 40 mg or etanercept
50 mg) with power Doppler (PDUS)-negative synovial
hypertrophy underwent synovial tissue biopsy. Patients
with RA with high/moderate disease naïve to treatment
(n=50) were included as a comparison group.
Immunostaining for cluster designation (CD)68, CD21,
CD20, CD3, CD31 and collagen was performed.
Results PDUS-negative patients with RA in remission
showed lower histological scores for synovial CD68+,
CD20+, CD3+ cells and CD31+ vessels and collagen
deposition (p<0.05 for both lining and sublining)
compared with PDUS-positive patients with RA with high/
moderate disease. In addition, there was no significant
difference in terms of lining and sublining CD68+,
CD20+, CD3+, CD31+ cells and collagen comparing
PDUS-negative patients with RA in remission and in LDA,
respectively. On the contrary, PDUS-negative patients with
PsA in remission showed higher histological scores for
sublining CD68+ (p=0.02) and CD3+ cells (p=0.04) as
well as CD31+ vessels (p<0.001) than PDUS-negative
patients with RA in remission.
Conclusions PDUS-negative patients with RA in
remission have comparable synovial histological features
than PDUS-negative patients with RA in LDA. However,
patients with PsA in remission are characterised by a
higher degree of residual synovial inflammation than
patients with RA in remission, despite PDUS negativity
under TNF inhibition.
INTRODUCTION
Stable clinical remission is the most important goal
in the treatment of chronic arthritides as rheumatoid
arthritis (RA) and psoriatic arthritis (PsA). However,
despite apparent clinical remission, defined with
composite indices, patients with RA can experience
joint damage progression.1 Ultrasound assessment
(US), through synovial membrane hypertrophy (SH)
and power Doppler (PDUS) evaluation, identifies
residual synovitis in more than 50% of patients with
RA in remission on the basis of their disease activity
score (DAS).1 It has been shown that significantly
fewer PDUS-negative patients with RA in clinical
remission had a flare during the 12-month follow-up
period, compared with patients with RAwith PDUS
positivity at the time of remission.2
The use of combined clinical and PDUS criteria
allows to identify patients with RA in remission,
increasing the success rate of persistence of the good
clinical outcome after tumour necrosis factor (TNF)
inhibitor discontinuation in patients with estab-
lished disease.3 The presence of SH seems to be a
frequent finding in patients with long-standing RA
with DAS-based remission, owing to the contribu-
tion of significant long-standing disease to SH.
However, data on the composition of residual syno-
vitis in patients with RA derive mostly from histo-
logical studies enrolling patients in remission with
PDUS-positive synovitis,4 and no data were pro-
duced on patients with PsA in stable clinical remis-
sion with PDUS-residual SH after standardised
treatments. Moreover, it is still unknown if PDUS-
negative patients with RAwith long-standing disease
in clinical remission differ from PDUS-negative
patients with RA in low disease activity (LDA)
reached with the same treatment regimen.
Based on this, the aims of the study were (i) to
define the histological features of PDUS-negative
synovial tissue of patients with RA and PsA in
clinical remission through anti-TNF treatment;
(ii) to dissect the correlations between US features
and inflammatory (CD68, CD21, CD20 and
CD3), vascular (CD31) and fibrotic (collagen)
synovial parameters and (iii) to assess the possible
histological differences in terms of inflammatory
synovial cells comparing patients with RA in
clinical remission and in LDA status with
PDUS-negative SH.
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PATIENTS AND METHODS
Patients recruitment
Patients with RA (n=25) fulfilling the American College of
Rheumatology 2010 revised criteria for RA5 in stable clinical
remission (DAS<1.6 for at least 6 months) or stable LDA
(n=10) (1.6<DAS<2.4 for at least 6 months), and patients
with PsA (n=18)6 in stable clinical remission (DAS<1.6 and
PASI=0 for at least 6 months) and stable minimal disease activ-
ity (MDA),7 were enrolled in the study. All patients were under
treatment with stable dose of methotrexate in association with
TNF-α inhibitor (adalimumab 40 mg/14 days or etanercept
50 mg/week, respectively). At study entry, each patient was
defined as in US remission with negative PDUS despite the pres-
ence of SH according to the published protocol.3 A comparison
group of 50 patients with RA naive to any Disease Modifying
Anti-Rheumatic Drugs (DMARDs) treatment, with high/moder-
ate disease activity with PDUS-positive SH, was included. The
study protocol was approved by the local ethical committee,
and all subjects provided signed informed consent.
Synovial tissue biopsy and immunohistochemistry for CD68,
CD21, CD20, CD3, CD31 and collagen
All enrolled patients underwent ultrasound-guided synovial
tissue biopsy of the knee following the already published proto-
col.8 Once collected, synovial tissue specimens were fixed in
10% neutral-buffered formalin and embedded in paraffin for
histology. Briefly, paraffin-embedded synovial tissue (ST) speci-
mens were sectioned at 3–4 μm. First, sections were stained for
H&E as follows: sections were deparaffinised in xylene and
rehydrated in a graded ethanol series. Then they were stained in
haematoxylin and counterstained in eosin/phloxine. Finally, sec-
tions were dehydrated, cleared in xylene and mounted with Bio
Mount (Bio-Optica). Other sections were stained for CD68
mouse antihuman monoclonal antibody (clone 514H12) or
CD21 mouse antihuman monoclonal antibody (clone 2G9) or
CD20 mouse antihuman monoclonal antibody (clone L26)
or CD3 mouse antihuman monoclonal antibody (clone LN10)
or CD31 mouse antihuman monoclonal antibody (clone 1A10)
(all from Leica Biosystem, Newcastle, UK) by immunostainer
BOND MAX III (Leica).9
ST slides were stained for collagen using the Masson
Trichrome Goldner with light green (Bio-Optica; 04-011802) as
follows: slides were washed in distilled water; then six drops of
Weigert’s iron haematoxylin, provided by the manufacturer,
were put on the sections and left to act 10 min. Without
washing, the slides were drained, and 10 drops of picric acid
alcoholic stable solution were added on the sections. Then, the
slides were quickly (3–4 s) washed in distilled water, and 10
drops of ponceau acid fuchsin according to Masson were added
on the sections and left to act 4 min. Then, the slides were
washed in distilled water, and 10 drops of phosphomolybdic
acid solution were added on the sections and left to act 10 min.
Without washing, the slides were drained, and 10 drops of
Light Green Solution, according to Goldner, were added and
left to act 5 min. Then, the slides were washed in distilled water
and rapidly dehydrated through ascending alcohols. Reaction
was done for 1 min in absolute alcohol. Finally, the slides were
cleared in xylene and mounted.
Slides were examined by two independent evaluators using a
light microscope (Leica DM 2000), and all tissues were evalu-
ated using a numerical score based on the number of CD68+,
CD21+, CD3+, CD20+ and CD31+ cells in the lining and sub-
lining areas of the section (three different fields in each section),
with a score of 0 indicating no positive cells; 1 indicating
<10% positive cells; 2 indicating 10%–50% positive cells; and
3 indicating >50% positive cells.10 The inter-rater agreement
coefficient was assessed for each single immunohistochemistry
(IHC) marker (see online supplementary table S1).








cohort (n=18) p Value* p Value** p Value*** p Value ^
Age, years (mean±SD) 57.20±14.95 52.00±16.38 54.36±15.33 56.67±16.66 0.45 0.69 0.37 0.80
Gender, female (%) 21 (84.0) 6 (60.0) 40 (80.00) 11 (61.1) 0.68 0.17 0.13 0.08
Disease duration, years (mean±SD) 9.70±2.81 9.52±3.03 2.19±2.82 8.50±3.01 <0.001 <0.001 0.06 0.89
Treatment duration, years (mean±SD) 7.01±3.41 6.98±2.75 – 6.83±2.95 – – 0.98 0.63
AB positivity, n (%) 17 (68.0) 5 (50.0) 28 (56.0) 0 (0.0) 0.31 0.72 0.27 <0.001
DAS (mean±SD) 1.09±0.40 1.90±0.31 3.52±1.10 1.10±0.53 <0.001 <0.001 <0.001 0.87
DAS28 (mean±SD) 2.17±0.82 3.18±0.48 5.00±1.24 2.16±0.86 <0.001 <0.001 <0.001 0.51
GH (mean±SD) 32.00±12.73 37.88±27.90 55.80±23.56 33.44±31.93 0.001 0.02 0.37 0.89
TJC28 (mean±SD) 0.04±0.20 1.20±1.23 7.14±6.21 0.39±0.61 <0.001 <0.001 0.01 0.10
TJC44 (mean±SD) 0.16±0.47 1.60±1.95 8.66±8.84 0.39±0.61 <0.001 <0.001 0.02 0.11
SJC28 (mean±SD) 0.12±0.33 1.00±1.05 7.04±6.03 0.22±0.43 <0.001 <0.001 0.02 0.38
SJC44 (mean±SD) 0.16±0.37 1.00±1.05 8.68±8.72 0.22±0.43 <0.001 <0.001 0.02 0.61
ESR, mm/first hour (mean±SD) 17.00±16.10 16.20±16.28 54.65±31.05 14.17±13.62 <0.001 <0.001 0.90 0.62
CRP, mg/L (mean±SD) 2.14±2.00 2.58±2.13 21.43±21.54 2.77±3.20 <0.001 0.002 0.53 0.96
BMI (mean±SD) 25.78±4.11 29.54±8.19 26.55±5.65 26.64±4.25 0.65 0.19 0.15 0.42
Treatment regimen
MTX dose, mg/week 14.42±3.56 14.38±4.96 – 14.79±3.45 – – 0.97 0.97
Etanercept 50 mg/week 13 (52.0) 6 (60.0) – 10 (55.6) – – 0.67 0.82
Adalimumab 40 mg/2 weeks 12 (48.0) 4 (40.0) – 8 (44.4) – – 0.67 0.82
p*: Patients with RA in remission versus patients with RA with high/moderate disease; p**: Patients with RA in LDA versus patients with RA with high/moderate disease; p***: Patients
with RA in remission versus patients with RA in LDA; p^: Patients with RA in remission versus patients with PsA in remission; Bold: p<0.05.
AB, autoantibody; BMI, body mass index; CRP, C reactive protein; DAS, disease activity score; ESR, erythrocyte sedimentation rate; GH, global health; LDA, low disease activity; MTX,
methotrexate; PsA, psoriatic arthritis; RA, rheumatoid arthritis; SJC, swollen joint count; TJC, tender joint count.
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Statistical analysis
Statistical analysis was performed using SPSS V. 20.0 (SPSS.
Chicago, Illinois, USA) and Prism software (GraphPad, San
Diego, California, USA). Categorical and quantitative variables
were described as frequencies, percentage and mean±SD. Data
on demographic and clinical features were compared between
patients by the non-parametric Mann-Whitney U test or χ2 test,
as appropriate. Spearman’s rank correlation test was used for
correlation in all analyses. A value of p<0.05 was considered
statistically significant.
RESULTS
Demographic, clinical and immunological characteristics
of enrolled patients
Demographic, clinical and immunological characteristics of the
enrolled patients with RA are summarised in table 1.
PDUS-negative patients with RA in remission and in LDA did
not differ for SH thickness in all the assessed joints (table 2)
and showed significantly lower DAS and DAS28 values
(p<0.001 and p<0.001, respectively), global health (GH)
assessment (p<0.001), tender joint count over 44 and 28 joints
(p<0.001 and p<0.001, respectively) and swollen joint count
over 44 and 28 joints (p<0.001 and p<0.001, respectively)
compared with patients with RA with high/moderate disease
activity. Patients with RA in clinical remission did not differ
from patients with RA in LDA in terms of age, gender, disease
duration and treatment duration (table 1). Using a stricter cri-
teria to define stable clinical remission (Simplified Disease
Activity Index (SDAI)≤3.3 for at least 6 months), 14/25 (56.0%)
patients with RA were considered to be in SDAI remission in
our cohort despite DAS-based definition. Analysing the different
parameters used for SDAI calculation, only the patient global
assessment of disease activity (p<0.001) was the item limiting
the achievement of SDAI remission in our PDUS-negative RA
cohort (see online supplementary table S2).
Histological features of synovial tissue do not differ in
PDUS-negative patients with RA in remission compared with
PDUS-negative patients with RA in LDA under TNF blockade
All included patients underwent synovial tissue biopsy of the
knee, which was assessed for the presence of resident CD68+,
CD21+, CD20+ and CD3+ cells. In figure 1A–C, example
images of immunostaining for CD68+, CD21+, CD20+ and
CD3+ cells in synovial tissue from patients with RA with high/
moderate disease, in LDA and in clinical remission, respectively
are shown. In particular, PDUS-negative patients with RA in







cohort (n=18) p Value* p Value**
Wrist
RC SH, mm (mean±SD) 1.53±0.88 1.54±1.06 1.31±0.61 0.98 0.37
RC SH score (mean±SD) 0.36±0.64 0.50±0.70 0.22±0.55 0.57 0.46
IC SH, mm (mean±SD) 2.39±1.14 2.75±1.33 2.74±0.54 0.43 0.23
IC SH score (mean±SD) 0.76±0.78 1.10±0.99 0.62±0.41 0.29 0.49
MCP-PIP (dorsal view)
II MCP SH, mm (mean±SD) 0.61±0.49 0.65±0.77 0.43±0.35 0.85 0.19
II MCP SH score (mean±SD) 0.50±0.51 0.67±0.50 0.51±0.48 0.44 0.95
III MCP SH, mm (mean±SD) 0.68±0.64 0.69±0.94 0.55±0.38 0.97 0.45
III MCP SH score (mean±SD) 0.75±0.53 0.78±0.67 0.54±0.52 0.89 0.20
II PIP SH, mm (mean±SD) 0.78±0.42 0.74±0.27 0.60±0.30 0.78 0.13
II PIP SH score (mean±SD) 0.38±0.67 0.10±0.20 0.34±0.36 0.21 0.45
III PIP SH, mm (mean±SD) 0.83±0.32 0.75±0.29 0.57±0.26 0.50 0.10
III PIP SH score (mean±SD) 0.22±0.43 0.25±0.46 0.23±0.44 0.62 0.98
MCP-PIP (volar view)
II MCP SH, mm (mean±SD) 0.45±0.53 0.84±0.71 0.47±0.54 0.10 0.91
II MCP SH score (mean±SD) 0.41±0.59 0.78±0.64 0.46±0.66 0.11 0.88
III MCP SH, mm (mean±SD) 0.43±0.47 0.20±0.21 0.39±0.43 0.15 0.91
III MCP SH score (mean±SD) 0.38±0.59 0.25±0.46 0.23±0.44 0.53 0.60
II PIP SH, mm (mean±SD) 0.79±0.54 0.51±0.45 0.63±0.36 0.16 0.54
II PIP SH score (mean±SD) 0.33±0.64 0.23±0.35 0.21±0.47 0.64 0.80
III PIP SH, mm (mean±SD) 0.76±0.37 0.61±0.53 0.57±0.38 0.35 0.61
III PIP SH score (mean±SD) 0.38±0.49 0.33±0.50 0.27±0.43 0.91 0.56
Knee
knee SH, mm (mean±SD) 6.50±2.91 8.01±2.59 5.50±2.41 0.16 0.34
MTP
II MTP SH, mm (mean±SD) 0.73±0.43 0.60±0.29 0.88±0.71 0.39 0.82
V MTP SH, mm (mean±SD) 0.30±0.34 0.30±0.36 0.37±0.44 0.99 0.87
p*: Patients with RA in remission versus patients with RA in LDA; p**: Patients with RA in remission versus patients with PsA in remission.
IC, intercarpal joint; LDA, low disease activity; MCP, metacarpal–phalangeal joint; MTP, metatarsal–phalangeal joint; PIP, proximal interphalangeal joint; PsA, psoriatic arthritis; RA,
rheumatoid arthritis; RC, radiocarpal joint; SH, synovial hypertrophy; US, ultrasound assessment.
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clinical remission showed lower histological scores for CD68+
cells (p<0.001 for both lining and sublining), CD20+ cells
(p<0.001 for lining and p=0.02 for sublining, respectively) and
CD3+ cells (p=0.002 for lining and p=0.003 for sublining)
compared with patients with RA with high/moderate disease
activity. PDUS-negative patients with RA in LDA showed lower
histological scores for lining (p=0.03) and sublining (p=0.01)
CD68+ cells, lining (p=0.01) and sublining (p=0.05) CD20+
cells (p=0.05) and lining (p=0.04) and sublining (p=0.05)
CD3+ cells compared with patients with RA with high/moderate
disease activity (figure 1D–I). In addition, follicular structures
were found in 8.0% of patients with RA in clinical remission
(p<0.001), 10.0% of patients with RA in LDA (p=0.01) com-
pared with 56.0% of patients with RA with high/moderate
disease activity. None of the synovial follicular structures found
in PDUS-negative patients with RA in clinical remission and
LDA was positive for CD21+ cells compared with 71.4% of
CD21+ synovial follicles in patients with RAwith high/moderate
disease activity (p≤0.001) (figure 1A–C).
Moreover, PDUS-negative patients with RA in clinical
remission did not differ from PDUS-negative patients with RA
in LDA in terms of histological scores for CD68+ cells
(p=0.39 and p=0.28), CD20+ cells (p=0.49 and p=0.65)
and CD3+ cells (p=0.92 and p=0.29), respectively, in the
lining and sublining areas (figure 1D–I). These findings were
confirmed dividing PDUS-negative patients with RA in re-
mission using the SDAI cut-off (see online supplementary
table S2).
Figure 1 (A–I) IHC staining for CD68/CD21 and CD3/CD20 on ST of patients with rheumatoid arthritis (RA) in disease remission, in low disease
activity (LDA) and in high/moderate disease. (A) Example photos of CD68 (red)/CD21 (brown) (Aa, b) and CD3 (red)/CD20 (brown) (Ac,d) staining of
ST biopsies from patients with RA with high/moderate disease activity naïve to any DMARDs treatment (magnification 20×). (B) Example photos of
CD68 (red)/CD21 (brown) (Ba, b) and CD3 (red)/CD20 (brown) (Bc,d) staining of ST biopsies from patients with RA in LDA status (magnification 20×).
(C) Example photos of CD68 (red)/CD21 (brown) (Ca, b) and CD3 (red)/CD20 (brown) (Cc,d) staining of ST biopsies from patients with RA in clinical
remission (magnification 20×); ultrasound assessment (US) picture with power doppler (PD) scale of the knee used for ST biopsy is shown next to
the corresponding patient. (D) Lining IHC score for CD68+ cells; high/moderate versus LDA patients with RA, *p=0.03; high/moderate versus
remission patients with RA, **p<0.001; LDA versus remission patients with RA, p=0.39. (E) Sublining IHC score for CD68+ cells; high/moderate
versus LDA patients with RA, **p=0.01; high/moderate versus remission patients with RA, **p<0.001; LDA versus remission patients with RA,
p=0.28. (F) Lining IHC score for CD20+ cells; high/moderate versus LDA patients RA, **p=0.01; high/moderate versus remission patients with RA,
**p<0.001; LDA versus remission patients with RA, p=0.49. (G) Sublining IHC score for CD20+ cells; high/moderate versus LDA patients with RA,
*p=0.05; high/moderate versus remission patients with RA, *p=0.02; LDA versus remission patients with RA, p=0.65. (H) Lining IHC score for CD3+
cells; high/moderate versus LDA patients with RA, *p=0.04; high/moderate versus remission patients with RA, **p=0.002; LDA versus remission
patients with RA, p=0.92. (I) Sublining IHC score for CD3+ cells; high/moderate versus LDA patients with RA, *p=0.05; high/moderate versus
remission patients with RA, **p=0.003; LDA versus remission patients with RA, p=0.29.
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PDUS-negative patients with RA in remission do not differ
from PDUS-negative patients with RA in LDA for synovial
CD31+ vessels under TNF inhibitors
At study entry, all enrolled patients with RA in remission and in
LDAwere PDUS-negative, regardless of SH presence. Performing
CD31 immunohistochemistry staining, both PDUS-negative
patients with RA in remission (figure 2Ca, b) and PDUS-negative
patients with RA in LDA (figure 2Ba, b) showed significantly less
CD31+ vessels compared with patients with RA with high/mod-
erate disease activity (figure 2Aa, b) (p<0.001 for both
PDUS-negative patients with RA in remission and in LDA versus
high/moderate patients with RA, respectively) (figure 2D).
Moreover, PDUS-negative patients with RA in remission did not
differ in terms of CD31+ vessels compared with PDUS-negative
patients with RA in LDA after TNF inhibitors (p=0.57)
(figure 2D).
PDUS-negative patients with RA in remission do not differ
from PDUS-negative patients with RA in LDA for synovial
collagen distribution under TNF inhibitor
To assess the rate of inflammation resolution in patients with RA
after TNF inhibition, we performed Masson Trichrome Goldner
staining for collagen distribution assessment in synovial tissue.
PDUS-negative patients with RA in remission (figure 3Ca, b)
showed significantly higher collagen deposition in the lining and
sublining areas (p<0.001 for both) compared with patients with
RA with high/moderate disease activity (figure 3Aa, b) (figure
3D–E). PDUS-negative patients with RA in LDA (figure 3Ba, b)
showed a higher extent of collagen deposition in the lining
(p=0.03) and sublining (p<0.001) areas (figure 3D–E)
compared with patients with RA with high/moderate disease
activity (figure 3D–E). Finally, PDUS-negative patients with RA
in remission did not differ in terms of collagen deposition com-
pared with PDUS-negative patients with RA in LDA under TNF
blockade (p=0.74 and p=0.61 for lining and sublining, respect-
ively) (figure 3E–D).
PDUS-negative patients with RA in remission have less
resident synovial CD68+, CD3+ and CD31+ cells compared
with PDUS-negative patients with PsA in remission under
TNF inhibitor
To assess the possible histological differences between residual
synovial inflammation in RA and other inflammatory diseases,
we compared synovial distribution of CD68+, CD21+, CD20+,
CD3+ and CD31+ cells of PDUS-negative patients with RA
(n=25) and PDUS-negative patients with PsA (n=18) in stable
clinical remission under TNF blockade. As shown in table 1,
there were no significant differences between PDUS-negative
patients with RA and PsA in remission according to demo-
graphic, clinical and inflammatory parameters (erythrocyte sedi-
mentation rate (ESR) and C reactive protein (CRP)) (table 1).
Moreover, PDUS-negative patients with RA and PsA did not
differ according to the SH thickness in all the assessed joints
(table 2).
As shown in figure 4A, B, despite similar US characteristics at
the time of study entry, PDUS-negative patients with PsA in
remission showed significantly higher degree of residual syno-
vitis compared with PDUS-negative patients with RA in remis-
sion in terms of CD68+, CD3+ and CD31+ cells distribution.
In particular, PDUS-negative patients with PsA in remission
Figure 2 (A–D) IHC for CD31+ vessels on ST of patients with rheumatoid arthritis (RA) in remission, in low disease activity (LDA) and in high/
moderate disease. (A) Example photos of CD31 (brown) staining of ST from patient with high/moderate RA (a, b) (magnification 20×); corresponding
ultrasound assessment (US) picture with PD scale (PD score=2) of the knee used for ST biopsy is shown. (B) Example photos of CD31 (brown)
staining of ST from patient with RA in LDA (a, b) (magnification 20×); corresponding US picture with PD scale (PD score=0) of the knee used for ST
biopsy is shown. (C) Example photos of CD31 (brown) staining of ST from patient with RA in remission (a, b) (magnification 20×); corresponding US
picture with PD scale (PD score=0) of the knee used for ST biopsy is shown. (D) IHC score for CD31+ vessels in ST of enrolled cohorts; high/
moderate versus LDA in patients with RA, **p<0.001; high/moderate versus remission in patients with RA, **p<0.001; LDA versus remission in
patients with RA, p=0.57.
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showed higher histological scores for sublining CD68+ cells
(p=0.02), sublining CD3+ cells (p=0.04) and CD31+ vessels
(p<0.001) compared with PDUS-negative patients with RA in
remission (figure 4C–I). Finally, in PDUS-negative patients with
PsA in remission, there was a direct correlation between the
histological scores of sublining CD3+ cells and sublining
CD68+ cells (r=0.86; p=0.02).
DISCUSSION
This study shows that PDUS-negative patients with RA in stable
remission and in LDA were characterised by similar degree of
histologically proven residual synovitis compared with
treatment-naïve patients with RA with high/moderate disease
activity and that PDUS-negative patients with RA and PsA in
stable clinical remission differed at the synovial tissue level in
terms of resident inflammatory cells and angiogenesis after TNF
inhibitors treatment.
Disease remission achievement is the most important goal in
RA treatment, and to date, evidence suggests that while TNF
blockers can be discontinued for some patients that have been
treated early in their disease course,11 stopping anti-TNF in
patients with RA with established disease leads to variable rates
of disease relapse.12 Based on that, it has been suggested that in
patients with RA with established disease, dose reduction may
be a more realistic approach and can be considered for patients
in remission or LDA, either by increasing the interval between
doses or reducing the dose administered.13 14
Clinical measures of disease remission alone, such as DAS
assessment, may underestimate the degree of synovitis, and the
systematic use of US is not justified in the follow-up of early
patients with RA.15 The combined use of US assessment in long-
standing patients with RA in clinical remission might increase
the success rate after anti-TNF tapering and discontinuation
compared with only DAS-based selection.3 16 17 It has been
demonstrated that ongoing synovitis can be detected by US in
up to 62% of patients with RA in clinical remission18–21 and
that PDUS-detected synovitis correlates with both progression
of structural damage22 and risk of subsequent RA flare.2
However, it is still unclear if this approach could lead to better
selection of patients with PsA achieving MDA status by
anti-TNF treatment for treatment tapering or discontinuation.
To date, there is no study on the synovial features of patients
with RA in clinical remission with PDUS-negative residual syno-
vitis, since limited data are available on the histological compos-
ition only of synovial tissue of patients with RA with stable
remission, with US-detected synovitis.4 Previous studies have
focused on the assessment of PDUS-positive residual synovitis in
patients with RA with stable remission including heterogeneous
RA cohorts, mainly in terms of therapeutic regimen (ie, conven-
tional and biological DMARDs). This may represent an import-
ant confounding factor influencing the rate of synovial
inflammatory cells whose survival may be differentially affected
by pharmacological therapy. To overcome this, at study entry,
we performed synovial tissue biopsy of patients with RA in
stable clinical and PDUS remission or LDA that were achieved
by combination therapy of methotrexate and TNF blockers, the
latter used as the first and only biological agent in the patients’
disease history.
Figure 3 (A–E) Masson Trichrome Goldner with light green immunostaining on ST of patients with rheumatoid arthritis (RA) in remission, in low
disease activity (LDA) and in high/moderate disease. (A) Example photos of collagen (green) staining of ST from high/moderate patient with RA
(a, b) (magnification 20×); corresponding ultrasound assessment (US) picture with PD scale (PD score=2) of the knee used for ST biopsy is shown.
(B) Example photos of collagen (green) staining of ST from patient with RA in LDA (a, b) (magnification 20×); corresponding US picture with PD
scale (PD score=0) of the knee used for ST biopsy is shown. (C) Example photos of collagen (green) staining of ST from patient with RA in remission
(a, b) (magnification 20×); corresponding US picture with PD scale (PD score=0) of the knee used for ST biopsy is shown. (D) Lining IHC score for
collagen in ST of enrolled cohorts; high/moderate versus LDA patients with RA, p=0.03; LDA versus remission patients with RA, p=0.10; high/
moderate versus remission patients with RA, p<0.001. (E) Sublining IHC score for collagen in ST of enrolled cohorts; high/moderate versus LDA
patients with RA, **p<0.001; LDA versus remission patients with RA, p=0.10; high/moderate versus remission patients with RA, **p<0.001.
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In the present study, using a combination of clinical and US
criteria in patients with long-standing RA, we have shown that
both patients with RA in remission and LDA showed less degree
of residual synovitis compared with patients with RA with high/
moderate disease activity. In particular, we found significant
higher frequency for the presence of follicular synovitis in the
latter compared with patients with RA in remission or in LDA.
Interestingly, synovial follicles, if present in PDUS-negative
patients with RA in remission or LDA, were not homing CD21+
follicular dendritic cells. Moreover, patients with RA in remis-
sion and LDA showed comparable degree of residual synovitis
with no significant differences in terms of resident CD68+,
CD21+, CD20+ and CD3+ cells.
In our study, we found that, if PD signal is absent at the time
of disease remission or LDA achievement, it is very likely that
synovial tissue is similar between RA in remission and LDA in
terms of CD68+, CD21+ CD20+, CD3+ and CD31+ cells.
Ramirez et al demonstrated that despite DAS-based remission
reached through various conventional and biological DMARDs,
patients with RA with PDUS-positive synovitis show a specific
biological profile characterised by an excess of angiogenic medi-
ators compared with patients with RA with PDUS-negative
Figure 4 (A–I) IHC staining for CD68/CD21, CD3/CD20 and CD31 on ST of power Doppler (PDUS)-negative patients with rheumatoid arthritis (RA)
and psoriatic arthritis (PsA) in disease remission. (A) Example photos of CD68 (red)/CD21 (brown) (Aa), CD3 (red)/CD20 (brown) (Ab) and CD31
(brown) (Ac) staining of ST biopsies from patients with RA in remission (magnification 20×); corresponding ultrasound assessment (US) picture with
PD scale (PD score=0) of the knee used for ST biopsy is shown. (B) Example photos of CD68 (red)/CD21 (brown) (Ba), CD3 (red)/CD20 (brown) (Bb)
and CD31 (brown) (Bc) staining of ST biopsies from patients with PsA in remission (magnification 20×); corresponding US picture with PD scale (PD
score=0) of the knee used for ST biopsy is shown. (C) Lining IHC score for CD68+ cells; patients with PsA versus RA, p=0.12. (D) Sublining IHC score
for CD68+ cells; patients with PsA versus RA, *p=0.02. (E) Lining IHC score for CD20+ cells; patients with PsA versus RA, p=0.13. (F) Sublining IHC
score for CD20+ cells; patients with PsA versus RA, p=0.22. (G) Lining IHC score for CD3+ cells; patients with PsA versus RA, p=0.29. (H) Sublining
IHC score for CD3+ cells; patients with PsA versus RA, *p=0.04. (I) IHC score for CD31+ vessels; patients with PsA versus RA, **p<0.001.
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remission,20 suggesting that the remaining synovial vascularity at
local joints may increase the risk of structural deterioration,
despite the anti-inflammatory therapy effect.23 24 These findings
confirm that remission in RA requires an improvement of
overall disease activity and disappearance of local synovial vas-
cularity detected by PDUS.
In addition, in our study, we reported for the first time the
histological features of synovial tissue from PDUS-negative
patients with PsA in stable remission (defined using an
RA-specific composite index as DAS) and MDA reached under
anti-TNF treatment. So far, formal criteria for remission of
patients with PsA have not been defined, whereas a state of
MDA has been proposed.7 Araujo et al25 recently demonstrated
that patients with PsA in stable clinical remission (defined as
having documented absence of clinical symptoms related to
arthritis, dactylitis, enthesitis and axial disease and minimal skin
disease with PASI<1) have a high chance of disease relapse after
treatment discontinuation, suggesting that patients with PsA
may be characterised by residual active synovitis. Moreover, the
authors suggested that the affected joints in patients with PsA
may repeatedly and effectively home inflammatory cells leading
to a memory function of the tissue, as the recurrence of the
disease usually occurs at the joints which were previously
affected by the disease. In our study, we performed synovial
tissue biopsy of the knee which was affected during the disease
course, showing that patients with PsA in remission are charac-
terised by a higher degree of residual synovitis in terms of
CD68+, CD3+ and CD31+ cells, mainly in the sublining, com-
pared with patients with RA in clinical remission despite stable
PDUS negativity, providing a biological support to the high rate
of disease relapse of patients with PsA after treatment discon-
tinuation.25 However, the analysis of the distribution of other
resident inflammatory cells, such as mast cells, demonstrated not
to be affected by TNF inhibition at synovial tissue level in spon-
dylarthritis,26 could provide additional information on the cellu-
lar composition of residual synovitis of patients with PsA in
MDA under TNF blockage.
In conclusion, the results of our study may have relevant
implications to better identify patients with RA in stable clinical
remission that could more safely undergo treatment reduction
or discontinuation using combined clinical and US selection cri-
teria. Moreover, since patients with RA with long-standing
disease reaching LDA status with PDUS-negative tissue have
comparable synovial characteristics than patients with RA in
remission, tapering anti-TNF agent could be a reasonable choice
for clinicians in such patients. However, to definitely confirm
the prognostic power of residual inflammatory cells in the syn-
ovial tissue of patients with RA or PsA in remission in foreseeing
disease relapse, prospective studies performing treatment taper-
ing or discontinuation, based on the combination of clinical, US
and histological selection criteria, are needed.
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